Novel drug development opportunities for heparin
Top Cited Papers
- 1 February 2002
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (2) , 140-148
- https://doi.org/10.1038/nrd724
Abstract
The glycosaminoglycan heparin has been used in the clinic as an anticoagulant for more than 50 years. A fully characterized sequence in native heparin is known to be responsible for this activity. However, heparin is a complex polysaccharide, which has an array of properties that are unrelated to its anticoagulant activity. Recent research has provided us with an increased understanding of the specific structural requirements for the various actions of heparin, indicating that it might be possible to create 'tailor-made' sequences based on the heparin template to isolate specific therapeutic activities. This research should provide the basis for novel drug treatments for a range of diseases, including cancer and various inflammatory diseases.Keywords
This publication has 97 references indexed in Scilit:
- Cloning and Expression Profiling of Hpa2, a Novel Mammalian Heparanase Family MemberBiochemical and Biophysical Research Communications, 2000
- Tissue distribution and antithrombotic activity of unlabeled or14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral routeCanadian Journal of Physiology and Pharmacology, 2000
- Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in ratsBlood Coagulation & Fibrinolysis, 2000
- Cloning and Functional Expression of a Human Heparanase GeneBiochemical and Biophysical Research Communications, 1999
- Optimal Timing of Hemodilution for Brain Protection in a Canine Model of Focal Cerebral IschemiaStroke, 1996
- Human Pharmacokinetics of Glycosaminoglycans Using Deuterium-Labeled and Unlabeled Substances: Evidence for Oral AbsorptionSeminars in Thrombosis and Hemostasis, 1994
- Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell‐mediated immunityEuropean Journal of Immunology, 1990
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- Heparin releases heparan sulfate from the cell surfaceBiochemical and Biophysical Research Communications, 1977
- The separation of active and inactive forms of heparinBiochemical and Biophysical Research Communications, 1976